Terms: = Sarcomas AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Treatment
134 results:
1. The immunomodulatory impact of naturally derived neem leaf glycoprotein on the initiation progression model of 4NQO induced murine oral carcinogenesis: a preclinical study.
Das J; Bera S; Ganguly N; Guha I; Ghosh Halder T; Bhuniya A; Nandi P; Chakravarti M; Dhar S; Sarkar A; Das T; Banerjee S; Ghose S; Bose A; Baral R
Front Immunol; 2024; 15():1325161. PubMed ID: 38585261
[TBL] [Abstract] [Full Text] [Related]
2. Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings.
Epeldegui M; Chang D; Lee J; Magpantay LI; Borok M; Bukuru A; Busakhala N; Godfrey C; Hosseinipour MC; Kang M; Kanyama C; Langat D; Mngqibisa R; Mwelase N; Nyirenda M; Samaneka W; Hoagland B; Campbell TB; Martínez-Maza O; Krown SE;
J Acquir Immune Defic Syndr; 2023 Oct; 94(2):165-173. PubMed ID: 37368929
[TBL] [Abstract] [Full Text] [Related]
3. [An exploratory clinical study of the efficacy and safety of tumor-infiltrating lymphocytes in the treatment of metastatic osteosarcoma].
Wang CR; Kang M; Xu J; Lyu Y; Jiang YF; Sun MX; Zuo DQ; Shen JK; Ma XJ; Sun W; Hua YQ; Cai Z
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2421-2427. PubMed ID: 36000370
[No Abstract] [Full Text] [Related]
4. Abnormal Function of Circulating Follicular Helper T Cells Leads to Different Manifestations of B Cell Maturation and Differentiation in Patients with Osteosarcoma.
Zhao G; Liang J; Cao J; Jiang S; Lu J; Jiang B
J Healthc Eng; 2022; 2022():3724033. PubMed ID: 35494526
[TBL] [Abstract] [Full Text] [Related]
5. Using a System Pharmacology Method to Search for the Potential Targets and Pathways of Yinqiaosan against COVID-19.
Cao LH; Jia XY; He HJ; Wang ZZ; Zhao YY; Yang X; Li XM; Miao MS
J Healthc Eng; 2022; 2022():9248674. PubMed ID: 35340244
[TBL] [Abstract] [Full Text] [Related]
6. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.
Ohira M; Hotta R; Tanaka Y; Matsuura T; Tekin A; Selvaggi G; Vianna R; Ricordi C; Ruiz P; Nishida S; Tzakis AG; Ohdan H
Cancer Immunol Immunother; 2022 Mar; 71(3):589-599. PubMed ID: 34282496
[TBL] [Abstract] [Full Text] [Related]
7. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients.
Aydin AM; Hall M; Bunch BL; Branthoover H; Sannasardo Z; Mackay A; Beatty M; Sarnaik AA; Mullinax JE; Spiess PE; Pilon-Thomas S
Int Immunopharmacol; 2021 May; 94():107481. PubMed ID: 33636562
[TBL] [Abstract] [Full Text] [Related]
8. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
Hennessy M; Wahba A; Felix K; Cabrera M; Segura MG; Kundra V; Ravoori MK; Stewart J; Kleinerman ES; Jensen VB; Gopalakrishnan V; Pena R; Quach P; Kim G; Kivimäe S; Madakamutil L; Overwijk WW; Zalevsky J; Gordon N
Int J Cancer; 2021 Apr; 148(8):1928-1937. PubMed ID: 33152115
[TBL] [Abstract] [Full Text] [Related]
9. An update on the safety of nivolumab for the treatment of advanced melanoma.
Czarnecka AM; Rutkowski P
Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
[No Abstract] [Full Text] [Related]
10. Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy.
Schroeder BA; Black RG; Spadinger S; Zhang S; Kohli K; Cao J; Mantilla JG; Conrad EU; Riddell SR; Jones RL; Yee C; Pollack SM
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32269142
[TBL] [Abstract] [Full Text] [Related]
11. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma.
Miura JT; Zager JS
Future Oncol; 2019 Nov; 15(32):3665-3674. PubMed ID: 31538818
[TBL] [Abstract] [Full Text] [Related]
12. Therapeutic effects of adriamycin combined with high-intensity focused ultrasound on osteosarcoma.
Wang C
J BUON; 2019; 24(2):826-831. PubMed ID: 31128042
[TBL] [Abstract] [Full Text] [Related]
13. [Nanotechnology-mediated immunochemotherapy with Ingenol-3-Mebutate for Systematic Anti-tumor Effects].
Yu M; Zhao M; Yu R; Chu S; Xu J; Xia M; Wang C
J Control Release; 2019 Jun; 304():242-258. PubMed ID: 31071376
[TBL] [Abstract] [Full Text] [Related]
14. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract] [Full Text] [Related]
15. Decreased expression of STAT5A predicts poor prognosis in osteosarcoma.
Guo Z; Tang Y; Fu Y; Wang J
Pathol Res Pract; 2019 Mar; 215(3):519-524. PubMed ID: 30638860
[TBL] [Abstract] [Full Text] [Related]
16. Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells.
Owens GL; Price MJ; Cheadle EJ; Hawkins RE; Gilham DE; Edmondson RJ
Cancer Immunol Immunother; 2018 Oct; 67(10):1519-1531. PubMed ID: 30039427
[TBL] [Abstract] [Full Text] [Related]
17. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.
Achkar T; Arjunan A; Wang H; Saul M; Davar D; Appleman LJ; Friedland D; Parikh RA
PLoS One; 2017; 12(12):e0190084. PubMed ID: 29261796
[TBL] [Abstract] [Full Text] [Related]
18. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WTN; Chen M; Modiano JF; Monjazeb AM; Lee DA; Murphy WJ
J Immunother Cancer; 2017 Dec; 5(1):98. PubMed ID: 29254507
[TBL] [Abstract] [Full Text] [Related]
19. Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
Meazza C; Cefalo G; Massimino M; Daolio P; Pastorino U; Scanagatta P; Morosi C; Podda M; Ferrari A; Terenziani M; Spreafico F; Casanova M; Parafioriti A; Collini P; Gandola L; Bastoni S; Biassoni V; Schiavello E; Chiaravalli S; Puma N; Bergamaschi L; Luksch R
Med Oncol; 2017 Nov; 34(12):191. PubMed ID: 29094224
[TBL] [Abstract] [Full Text] [Related]
20. Potency-matched Dual Cytokine-Antibody Fusion Proteins for Cancer Therapy.
De Luca R; Soltermann A; Pretto F; Pemberton-Ross C; Pellegrini G; Wulhfard S; Neri D
Mol Cancer Ther; 2017 Nov; 16(11):2442-2451. PubMed ID: 28716814
[TBL] [Abstract] [Full Text] [Related]
[Next]
